That Grey-Market Peptide Your VC Buddy Injects Is Telehealth’s Next $30B Jackpot

(SeaPRwire) –

By: Oliver Hawthorne

I sat across from a consumer tech VC at a casual weekday breakfast last week. He rolled up his shirt sleeve mid-bite of toast. He swapped a small, unlabeled glass vial between his fingers. The vial held an experimental, grey-market peptide protocol. He sourced it from a seller he found on a niche biohacker forum. He swore it fixed chronic knee pain that had lingered for years. He said it cut his post-travel jet lag from three days to half a day. That unlabeled vial sits at the center of the biggest fight in telehealth right now. The sector is still reeling from coming GLP-1 compounding restrictions. Hims & Hers saw its stock hammered repeatedly over the last year. Regulators first declared the GLP-1 supply shortage over. They later proposed pulling GLP-1s from the pharmacy compounding list entirely. A final decision on that rule is pushed to July 30. Billions in easy telehealth revenue is about to dry up. Investors and operators are scrambling to find the next big growth driver. No one wants to say the quiet part out loud. That driver is already everywhere. It’s in gym bags, biohacker group chats, and startup office fridges. It just operates entirely outside legal, regulated channels right now.

The FDA’s compounding advisory committee will meet July 23 and 24. Members will review seven high-demand wellness peptides for compounding approval. The list includes BPC-157 and TB-500. Those are the two injectables name-dropped by every popular biohacker and RFK Jr. for the last three years. A positive vote would let licensed specialty pharmacies legally mix and dispense these compounds to patients. Hims & Hers is not waiting for the final gavel to position itself. The company confirmed its chief medical officer Dr. Anant Vinjamoori will testify at the Thursday hearing. Back in April, Hims released a public statement about its peptide plans. The company said it believes select peptide therapies hold real potential to help Americans live healthier lives. Michelle Davey is CEO of telehealth infrastructure firm Wheel. She says Hims’ move is not a surprise to anyone paying attention. She points to the company’s consistent public messaging around expanded wellness offerings. Davey cited Needham research sizing the full peptide market at roughly $30 billion. That figure covers existing grey market sales, peptides used as GLP-1 add-ons, and general health optimization demand. The peptide market will not follow the exact GLP-1 playbook, though. GLP-1 patients take one standardized shot per week. Most regular peptide users stack three, four, even five separate compounds at a time. There is effectively no long-term safety data for these stacked regimens. Most popular peptides have never gone through large, controlled human clinical trials. For years, sellers have peddled them as “research chemicals” to skirt standard drug approval rules. Davey laid out a clear 12-month timeline for a post-approval market. First, a flood of copycat telehealth sites will launch generic peptide programs. That will mirror the late 2024 GLP-1 rush. Back then, more than 80 founders launched GLP-1 clinics off basic Shopify storefronts. Roughly six months after that initial flood, well-capitalized platforms will pull ahead. They will compete on transparent pricing, verified pharmacy sourcing, and clinical credibility. The small, unvetted operators will either sell to larger players or close up shop entirely.

Jon Keidan is founder and managing partner of Torch Capital. His firm is one of the top investors in direct-to-consumer telehealth giant Ro. He sees the same consolidation dynamic playing out across the peptide space. He says compliance creates clear winners for every group involved. Consumers get sterile, accurately dosed products that match label claims. Legitimate operators get a sustainable, licensed business model. Those models won’t vanish overnight after one regulatory crackdown. Regulators get visibility into a market that currently operates entirely off the books. Keidan’s core read on the vote cuts through all the lobbying noise. The advisory committee can vote to approve compounding or reject it. Consumer demand for these peptides will not disappear either way. The only real choice on the table is where that demand flows. It can move into regulated, doctor-supervised channels with clear safety guardrails. Or it can stay locked in the grey market. There, unvetted sellers ship untested vials to anyone with a credit card. The telehealth players already positioning for peptides know this. They are not betting solely on a yes vote. They are betting that demand is too big, too loud, too established to suppress. A no vote will not erase the $30 billion market. It will just hand all that revenue to unregulated Telegram sellers, black-market labs, and fly-by-night sites that skip medical oversight entirely. A yes vote will not eliminate risk, either. The lack of long-term combination safety data will create real patient harm in the first two years of legal sales. That harm will trigger tighter rules, higher compliance costs, and a faster consolidation timeline than anyone currently models. The winners will not be the first sites to throw up a peptide landing page. They will be the platforms that build enough clinical guardrails to survive the first round of bad press. They will weather the first FDA warning letters, the first wave of patient adverse event reports. The GLP-1 era taught telehealth a brutal lesson. Revenue built on temporary regulatory loopholes vanishes overnight. Revenue built on compliant, monitored care sticks around long enough to build multibillion-dollar businesses.

Author bio: Oliver Hawthorne, Principal Correspondent covering digital health and consumer tech for a global technology review, with 12 years of embedded industry reporting experience.